Finanzen von Resmed Inc (RMD)RMDResmed Inc

ResMed Inc. (RMD) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Devices, accounting for 51.4% of total sales, equivalent to $735.75M. Another important revenue stream is Masks and other. Understanding this composition is critical for investors evaluating how RMD navigates market cycles within the Advanced Medical Equipment & Technology industry.

Evaluating the bottom line, ResMed Inc. maintains a gross margin of 58.12%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 31.04%, while the net margin is 26.20%. These profitability ratios, combined with a Return on Equity (ROE) of 24.27%, provide a clear picture of how effectively RMD converts its operational activities into shareholder value.

In the context of the broader market, RMD competes directly with industry leaders such as DXCM and ILMN. With a market capitalization of $34.01B, it holds a leading position in the sector. When comparing efficiency, RMD's gross margin of 58.12% stands against DXCM's 63.44% and ILMN's 66.44%. Such benchmarking helps identify whether ResMed Inc. is trading at a premium or discount relative to its financial performance.

ResMed has shown steady revenue growth, with Q2 revenue reaching $1.46 billion, an 8.6% year-on-year increase. However, the operating margin has decreased from 33.7% to 30.7% year-over-year, indicating some pressure on profitability.